Stockreport

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Altimmune, Inc. (Nasdaq:ALT), please note that the r [Read more]